Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of intravitreal Lucentis (ranibizumab) in early central retinal vein occlusion
2009-011403-23Phase 3Completed
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Jul 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ranibizumab in central retinal vein occlusion (CRVO), sponsored by Centre Hospitalier Intercommunal de Créteil. Primary endpoint: Change in visual acuity at 6 months. Started Jul 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2009-011403-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011403-23.